What Creative Industries Can Learn from How Pharma Protects Its IP

There is a document type in pharmaceutical research that has no real equivalent in the creative industries, and it probably should.

It is the laboratory notebook. Not the notebook as most people imagine it — a scientist scribbling in the margins — but the notebook as a controlled instrument. Bound, not loose-leaf, so pages cannot be added or removed. Written in ink. Filled in as the work happens, not afterwards. Signed and dated by the person doing the work, then countersigned by a witness who understood what they were reading. In large research organisations, this is not a personal habit. It is policy, it is audited, and people are trained in it before they are allowed near an experiment.

Pharma does this because the economics leave no alternative. A drug programme can run for a decade and cost well into the billions before anything reaches a patient, and the entire return on that spend rests on a bundle of rights that can be challenged, invalidated, or claimed by someone else. So the industry built systems to answer a specific question, in advance, with evidence: who did what, and when?

Creative work rests on exactly the same question. We just don’t behave as if it does.

The lesson is not “file more patents”

Let’s dispose of the obvious misreading first. Nobody is suggesting a graphic designer should be filing patents, or that a songwriter needs a regulatory affairs department. The legal mechanisms are different and mostly not transferable. Copyright, unlike a patent, arrives automatically the moment a work is fixed in a tangible form. There is nothing to file.

But that automatic protection is precisely where the complacency comes from. Because the right appears without effort, creators assume the proof of the right does too. It doesn’t. Copyright gives you ownership; it doesn’t give you the ability to demonstrate ownership to a sceptical third party three years later. Those are separate problems, and only one of them solves itself.

Pharma never had the luxury of that confusion. When your right depends on being able to show your work, you build a habit of showing your work.

What the disciplines actually are

Strip away the regulatory language and pharma’s documentation practice comes down to a handful of principles. Regulators including the FDA and the MHRA describe good record-keeping using a framework often shortened to ALCOA+: records should be attributable, legible, contemporaneous, original and accurate — plus complete, consistent, enduring and available.

Read that list again with a studio in mind rather than a lab.

Attributable. Every entry is linked to a named person. Not “the team,” not “the account.” A person. In creative work, attribution is the whole ballgame — in authorship disputes, in freelance-versus-employee arguments, in the increasingly common question of which parts of a piece a human actually made.

Contemporaneous. Recorded as it happens. This is the one that matters most and is ignored most. A record created at the moment of the decision is evidence. The same record reconstructed six months later, after a problem emerges, is a recollection — and it looks like one.

Original and enduring. The first capture, kept in a form that survives. Not the tidied version. Not the flattened export. The industry’s electronic systems are built so that entries cannot be silently overwritten; an edit is a new, timestamped event sitting on top of the old one, with the old one still visible. That audit trail is the point. A file you can quietly resave is not a record of anything.

Chain of custody. Where a sample or a dataset went, who handled it, and what they did with it. In creative production, this is the brief that came in, the version that went to the client, the revision the freelancer sent back, the asset the sub-contractor delivered. Agencies and studios handle other people’s IP constantly and hand their own IP to other people constantly, usually with no continuous record of either.

None of that is exotic. It is just deliberate.

The bit that surprises people

Here’s a wrinkle worth knowing, because it makes the argument stronger rather than weaker.

In 2013, US patent law moved from a first-to-invent system to a first-inventor-to-file one. Under the old rules, a dated and witnessed notebook could win you a priority contest against someone who filed before you. Under the new rules, that particular use largely disappeared. A reasonable person might have expected the notebook discipline to erode.

It didn’t. It persists because the documentation was never only about priority. It underpins who is correctly named as an inventor. It supports trade secret protection, which requires you to show a secret existed and that you took steps to protect it. It defends against allegations that an idea was derived from someone else. It survives due diligence, where an acquirer’s lawyers will ask for the provenance of every asset they are paying for.

The record outlived the specific rule that created it, because a good record is useful in every dispute, not one.

That is the real transferable insight. Creative businesses tend to think about documentation reactively — when there’s an infringement, when a client questions an invoice, when a collaborator’s memory diverges from yours. Pharma treats it as infrastructure, maintained regardless of whether a dispute ever arrives. Most of the time, nothing happens. That is what success looks like.

What good looks like, in practice

For studios, agencies and professional creators, the transferable practice is fairly short:

• Capture at the moment, not in retrospect. Contemporaneous is the single highest-value property a record can have. A timestamped sequence created while you worked is worth more than a comprehensive folder assembled afterwards.
• Name the human. Attribute every meaningful contribution to an individual, especially where freelancers, collaborators or AI tools are in the mix. “The studio made it” is not an answer to a question about authorship.
• Keep the versions, don’t overwrite them. The rejected route, the abandoned direction, the draft that changed everything — that sequence is your proof of independent creation. It is also, incidentally, the most persuasive evidence that a person made the work.
• Record the decision, not just the output. A line explaining why you changed direction carries more weight than the change itself. It shows judgement, which is the thing law and clients are both actually looking for.
• Document what came in, not just what went out. References, licensed assets, briefs, third-party contributions. Clean provenance on your inputs is what stops someone else’s problem becoming yours.
• Make it a system, not a virtue. Pharma doesn’t rely on individual conscientiousness; it builds the record into the workflow. Any documentation practice that depends on someone remembering to be diligent at the end of a difficult week will fail in exactly the week you needed it.

That last point is why we built CertifyIP the way we did: a secure, timestamped trail generated as the work happens, so the record exists before anyone thinks to ask for it.

The pharmaceutical industry didn’t develop these habits because scientists are tidier than designers. It developed them because it understood, earlier than most, that value which cannot be evidenced is value you may not get to keep.

Creative work has now arrived at the same place. The systems are simpler and the stakes look smaller, right up until the moment they don’t.